Today: 21 June 2026

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Dominion Energy in Focus on NextEra $76-a-Share Bid Rumor

Dominion Energy in Focus on NextEra $76-a-Share Bid Rumor

Dominion Energy traded at $69.00 in U.S. pre-market Monday, up nearly 12%, after reports that NextEra Energy is discussing a mostly stock offer near $76 a share, valuing Dominion at about $66 billion. The offer would give NextEra holders about 75% of the combined company. Dominion closed Friday at $61.73. The reported deal comes as U.S. power demand hits records, driven by data center growth.
18 May 2026
···
ServiceNow Draws Attention Ahead of Monday Opening

ServiceNow Draws Attention Ahead of Monday Opening

ServiceNow shares closed at $95.07 Friday after a 5.05% jump, outpacing major indexes but still trading 55% below last July’s high. Trading volume reached 34.2 million shares, well above average. Investors are weighing new AI product launches and raised 2026 subscription revenue guidance against ongoing concerns about margins and software market disruption.
18 May 2026
·
Riot Platforms’ AI spending puts pressure on Bitcoin investors

Riot Platforms’ AI spending puts pressure on Bitcoin investors

Riot Platforms shares last traded at $23.49, valuing the company at $8.2 billion, as it shifts from bitcoin mining to AI data-center leasing. AMD expanded its lease at Riot’s Rockdale, Texas site to 50 megawatts, with contract value potentially reaching $1 billion. Riot and Terrestrial Energy signed an MOU to explore data centers powered by small modular nuclear reactors. Jefferies rated Riot at hold with a $24 price target.
18 May 2026
····
Ryanair Cautions on Summer Fares, Puts Focus on Low-Cost Flights in Europe

Ryanair Cautions on Summer Fares, Puts Focus on Low-Cost Flights in Europe

Ryanair warned peak summer fares will be flat, reversing earlier expectations of a rise, citing late bookings and fuel costs. Shares fell over 3% despite record annual profit of 2.26 billion euros. The airline hedged 80% of its jet-fuel needs but declined to issue a 2027 profit forecast, citing ongoing volatility. Revenue rose 11% to 15.54 billion euros, with passenger traffic up 4%.
18 May 2026
·
Destiny Tech100 Gains Pre-Market as SpaceX IPO Buzz Mixes With AI Stock Warnings

Destiny Tech100 Gains Pre-Market as SpaceX IPO Buzz Mixes With AI Stock Warnings

Destiny Tech100 Inc. shares rose 10.6% to $52.68 in early premarket trading Monday after reports that SpaceX may list on Nasdaq as soon as June 12 at a $1.75 trillion valuation. DXYZ’s portfolio includes about 14.4% exposure to SpaceX and 18.1% to Anthropic. The stock ended last week down 13% despite sharp swings. Destiny’s shares last closed at nearly double their reported net asset value.
18 May 2026
····
Li Auto shares drop after L9 launch

Li Auto shares drop after L9 launch

Li Auto shares fell about 14% in Hong Kong on Monday, closing near HK$65 after investors reacted coolly to the launch of its updated L9 SUV. The drop came ahead of the company’s first-quarter results, scheduled for May 28, and amid ongoing price competition in China’s electric vehicle market.
18 May 2026
··
UnitedHealth Falls Premarket as Berkshire Sells Stake

UnitedHealth Falls Premarket as Berkshire Sells Stake

UnitedHealth shares dropped 4.8% to $375.06 in early premarket trading Monday after Berkshire Hathaway disclosed it sold its stake in the insurer. The move follows UnitedHealth’s recent rally to near a 52-week high and comes ahead of the NYSE core session. Berkshire’s sale was part of a broader first-quarter portfolio reshuffle. UnitedHealth closed Friday at $393.85.
18 May 2026
·
Super Micro Shares Slip, Eyes on Monday for SMCI

Super Micro Shares Slip, Eyes on Monday for SMCI

Super Micro Computer shares closed at $31.04 Friday, down 6% on the day and 12.2% since May 8, as the Nasdaq fell 1.54%. The company reports $10.24 billion in March-quarter sales, missing analyst estimates and down from $12.7 billion the prior quarter, with a 9.9% gross margin and $6.6 billion in operating cash outflow. Management will address investors Monday at a J.P. Morgan conference.
18 May 2026
·
IonQ’s Volatile Week Leaves Bulls Focused on Monday Trade

IonQ’s Volatile Week Leaves Bulls Focused on Monday Trade

IonQ shares closed Friday at $51.95, down 9.6% for the day but up 5.5% from the prior week. The company reported first-quarter revenue of $64.7 million, up 755% year-over-year, and raised full-year guidance to as much as $270 million. IonQ posted a GAAP net income of $805.4 million but an adjusted EBITDA loss of $96.8 million. Investor focus remains on high spending and cash burn.
18 May 2026
···
Ambev Slides After Initial Earnings Jump; Eyes on Next Week’s Test

Ambev Slides After Initial Earnings Jump; Eyes on Next Week’s Test

Ambev shares closed Friday at 15.69 reais, down 0.51%, with a five-day loss of 3.86% but up 13.20% year-to-date. First-quarter net profit rose 2.1% to 3.89 billion reais, helped by Carnival and strong premium beer sales. The Ibovespa fell 0.61% Friday, setting a weaker backdrop for Monday’s open. Trading volume for Ambev reached about 31 million shares at the last close.
17 May 2026
Apellis Exits Nasdaq; $41 Takeover Wraps, One Bet Left

Apellis Exits Nasdaq; $41 Takeover Wraps, One Bet Left

Biogen completed its acquisition of Apellis Pharmaceuticals last week, delisting Apellis from Nasdaq after accepting 82.4% of shares in a $41-per-share cash deal plus a contingent value right. Apellis became a Biogen subsidiary on May 14. The CVR will pay holders up to $4 if Syfovre sales meet specified targets. Biogen shares closed at $192.95 on Friday.
17 May 2026
··
1 … 49 50 51 52 53 … 872

Stock Market Today

  • Telix Pharmaceuticals Deepens Neuro-Oncology Focus with United Imaging Collaboration
    June 21, 2026, 5:26 AM EDT. Telix Pharmaceuticals (ASX:TLX) has signed a U.S. research collaboration with United Imaging Healthcare, aiming to integrate advanced scanning, AI, and its molecular imaging product TLX101-Px for glioma characterization. This partnership supports Telix's theranostics strategy, combining therapy and diagnostics to improve neuro-oncology patient management. The collaboration complements the upcoming FDA decision on TLX101-Px, set for September 11, 2026, a key catalyst for Telix's growth. Despite positive outlooks forecasting A$1.2 billion revenue by 2029, concerns persist over pricing pressures in prostate-specific membrane antigen (PSMA) imaging and operational risks. Investor views vary, reflecting uncertainties around margin expansion and execution timing but affirming Telix's potential leverage of imaging innovation and regulatory milestones.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 21.06.2026

21 June 2026
LIVEMarkets rolling coverageStarted: June 21, 2026, 4:00 AM EDTUpdated: June 21, 2026, 5:26 AM EDT Telix Pharmaceuticals Deepens Neuro-Oncology Focus with United Imaging Collaboration June 21, 2026, 5:26 AM EDT. Telix Pharmaceuticals (ASX:TLX) has signed a U.S. research collaboration with United Imaging Healthcare, aiming to integrate advanced scanning, AI, and its molecular imaging product TLX101-Px for glioma characterization. This partnership supports Telix’s theranostics strategy, combining therapy and diagnostics to improve neuro-oncology patient management. The collaboration complements the upcoming FDA decision on TLX101-Px, set for September 11, 2026, a key catalyst for Telix’s growth. Despite positive outlooks forecasting A$1.2 billion revenue
Go toTop